SecBot SecBot

PRAX

Praxis Precision Medicines, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001689548 Biotech & Drug Discovery
$310.27 −17.86 (−5.44%)
Nov 16 4:00 PM ET · prev $328.13
Market cap
$9.1B
Mid cap
Consensus
Buy
89% Buy or better · 27 analysts
Median target
🔒 Subscribers only
1 year
+57.0%
from $197.58 · Nov 17
30 days
+19.3%
from $260.17
52-week range
$164.09–386.33
−20% from high · low Nov 20
Avg volume 20D
480.0K
shares / day
Short interest
4.21M
≈15.1% of shares · +7.3%
Days to cover
8.7
at average volume
Insider net
−$3.6M
0 buyers · 1 seller · 12 mo
New fund stakes
4
Q3 2026 13F · 1 exit
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 1 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 4/6 ·Next FDA decision date, Dec 27, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $3.6M.

  • InstitutionsBULLISH

    Q3 2026: 42 added (4 new), 14 trimmed or exited. Largest new: Quadrature Capital $14.6M, Fiera Capital $11.7M.

  • AnalystsBULLISH

    24 of 27 rate it Buy or better.

  • EstimatesFLAT

    Current-quarter EPS estimate −$3.635 → −$3.635 over 90 days.

  • Short sellersSTEADY

    Short interest +7.3% to 4.21M shares. 8.7 days to cover, ≈15.1% of shares.

  • TrendUPTREND

    7% above its 50-day average.

Who's buying

13F· Q3 2026
4
new positions
1
exit
$36.3M
in new stakes · top 3 shown
FundMoveSharesValue
FRANKLIN TEMPLETON INCADD582,355$165.8M
WESTFIELD CAPITAL MANAGEMENT CO LPADD382,278$111.3M
MARSHALL WACE, LLPADD221,602$64.5M
Qube Research & Technologies LtdTRIM101,674$29.6M
Aberdeen Group plcTRIM96,291$28.0M
JANE STREET GROUP, LLCDOUBLED81,450$23.7M
Nuveen, LLCTRIM69,923$20.4M
JUPITER ASSET MANAGEMENT LTDDOUBLED55,529$16.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

27 analysts
Buy 89% rate it Buy or better
Strong Buy9Buy15Hold2Sell0Strong Sell1

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 10, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Nov 10, 2026Wedbush
MAINTAIN
MAINTAINUnderperform
Nov 10, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Nov 9, 2026BTIG
REITERATE
REITERATEBuy

Washington

Corporate Lobbying

11 lobbying filings and 4 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$3.6M
sold · 1 insider
DateInsiderTypeValue
Jul 8, 2026
Souza Marcio
Chief Executive Officer
Jul 8, 2026
GIFT2,600 sh
Jul 8, 2026
Souza Marcio
Chief Executive Officer
Jul 8, 2026
GIFT20,521 sh
Jun 24, 2026
DeSimone Jill
Director
Jun 24, 2026
EXERCISE$379.0K
Jun 24, 2026
DeSimone Jill
Director
Jun 24, 2026
SELL$3.0K
Jun 24, 2026
DeSimone Jill
Director
Jun 24, 2026
EXERCISE$446.9K
Jun 24, 2026
DeSimone Jill
Director
Jun 24, 2026
SELL$36.4K
Jun 24, 2026
DeSimone Jill
Director
Jun 24, 2026
SELL$97.7K
Jun 24, 2026
DeSimone Jill
Director
Jun 24, 2026
SELL$209.5K

Earnings setup

Estimates
−$3.63
EPS estimate, this quarter
0%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$3.63-$5.60–-$2.74-0.1%$0.00
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
4,207,692
shares short
+7.3%
vs prior settlement
8.7
days to cover
≈15.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Praxis Precision Medicines hosted an Investor Day on November 12, 2026, presenting commercial launch plans for two…
8-K · Impact 4/10
Nov 12, 2026 Other
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of Dece
Nov 9, 2026 SEC
Praxis Precision Medicines reported Q3 2026 net loss of $94.2M ($3.23 per share), wider than the $73.9M loss a year…
PRESS-RELEASE · Impact 4/10
Nov 4, 2026 Press
Praxis Precision Medicines granted 23,219 restricted stock units to 59 new non-executive employees under its 2024…
Impact 1/10
Sep 30, 2026 Inst.
FRANKLIN TEMPLETON INC · ADD
582,355 shares ($165.8M)
Sep 30, 2026 Inst.
WESTFIELD CAPITAL MANAGEMENT CO · ADD
382,278 shares ($111.3M)
Jul 8, 2026 Insider
Souza Marcio gifted 2,600 shares
Chief Executive Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
9 drugs tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

11 filings · 5 press releases · 3 bullish · 2 bearish · 1 mixed · 5 neutral
All PRAX filing & press-release reports (16)